Expertise in
4
conditions

Dr. Craig L. Slingluff

General Surgery
UVA Health Emily Couric Clinical Cancer Center
1240 Lee St, 
Charlottesville, VA 
Expertise in
4
conditions
UVA Health Emily Couric Clinical Cancer Center
1240 Lee St, 
Charlottesville, VA 

Overview

Craig Slingluff is a General Surgeon practicing medicine in Charlottesville, Virginia.

Dr. Slingluff is highly rated in 4 conditions, according to our data. His clinical expertise encompasses Melanoma, Merkel Cell Carcinoma, Eccrine Porocarcinoma, Neuroendocrine Tumor, and Tissue Biopsy.

He is actively involved in clinical research, co-authoring 167 peer reviewed articles and participating in 8 clinical trials.

Specialties

General Surgery

Licenses

Surgery in VA

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

HealthKeepers
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Piedmont
  • HMO
  • POS

Locations

UVA Health Emily Couric Clinical Cancer Center
1240 Lee St, Charlottesville, VA 22908

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

Enhanced Melanoma Vaccine Against Neoantigen and Shared Antigens by CD40 Activation and TLR Agonists in Patients With Melanoma
Enhanced Melanoma Vaccine Against Neoantigen and Shared Antigens by CD40 Activation and TLR Agonists in Patients With Melanoma
Enrollment Status: Completed
Publish Date: July 16, 2024
Intervention Type: Drug
Study Drugs: 6MHP, NeoAg-mBRAF, PolyICLC, CDX-1140
Study Phase: Phase 1/Phase 2
Open Label, Randomized, Phase I/II Study of a Long Peptide Vaccine Plus TLR Agonists for Resected Stage IIb-IV Melanoma. (MEL60)
Open Label, Randomized, Phase I/II Study of a Long Peptide Vaccine Plus TLR Agonists for Resected Stage IIb-IV Melanoma. (MEL60)
Enrollment Status: Completed
Publish Date: February 28, 2024
Intervention Type: Other, Biological
Study Drug: Peptide Vaccine (LPV7) + Tetanus Peptide
Study Phase: Phase 1/Phase 2
A Trial to Evaluate the Immunogenicity and Safety of a Melanoma Helper Peptide Vaccine Plus Novel Adjuvant Combinations (MEL63)
A Trial to Evaluate the Immunogenicity and Safety of a Melanoma Helper Peptide Vaccine Plus Novel Adjuvant Combinations (MEL63)
Enrollment Status: Terminated
Publish Date: October 30, 2023
Intervention Type: Drug, Biological
Study Phase: Phase 1/Phase 2
A Trial to Evaluate the Safety, Immunogenicity, and Clinical Activity of a Helper Peptide Vaccine Plus PD-1 Blockade
A Trial to Evaluate the Safety, Immunogenicity, and Clinical Activity of a Helper Peptide Vaccine Plus PD-1 Blockade
Enrollment Status: Completed
Publish Date: August 25, 2023
Intervention Type: Drug, Biological
Study Phase: Phase 1/Phase 2
Analysis of the Kinetics and Effects of Vemurafenib + Cobimetinib on Intratumoral and Host Immunity in Patients With Advanced BRAFV600 Mutant Melanoma: Implications for Combination With Immunotherapy
Analysis of the Kinetics and Effects of Vemurafenib + Cobimetinib on Intratumoral and Host Immunity in Patients With Advanced BRAFV600 Mutant Melanoma: Implications for Combination With Immunotherapy
Enrollment Status: Terminated
Publish Date: February 26, 2019
Intervention Type: Drug
Study Phase: Phase 2
A Phase II Pilot Trial of an Indoleamine 2,3, Dioxygenase-1 (IDO1) Inhibitor (INCB024360) Plus a Multipeptide Melanoma Vaccine (MELITAC 12.1) in Patients With Advanced Melanoma
A Phase II Pilot Trial of an Indoleamine 2,3, Dioxygenase-1 (IDO1) Inhibitor (INCB024360) Plus a Multipeptide Melanoma Vaccine (MELITAC 12.1) in Patients With Advanced Melanoma
Enrollment Status: Completed
Publish Date: June 08, 2018
Intervention Type: Biological, Drug
Study Phase: Phase 2
This is an Open-label, Phase II Study of a Vaccine Comprising Melanoma Peptides and a Tetanus Helper Peptide, Administered in GM-CSF-in-adjuvant. Patients Will be Randomized to Receive One of Two Different Vaccine Regimens. Patients Will be Stratified by Stage of Disease (IIB vs. III vs. IV).
This is an Open-label, Phase II Study of a Vaccine Comprising Melanoma Peptides and a Tetanus Helper Peptide, Administered in GM-CSF-in-adjuvant. Patients Will be Randomized to Receive One of Two Different Vaccine Regimens. Patients Will be Stratified by Stage of Disease (IIB vs. III vs. IV).
Enrollment Status: Completed
Publish Date: May 02, 2018
Intervention Type: Biological
Study Phase: Phase 2
View 6 Less Clinical Trials

167 Total Publications

ASO Visual Abstract: Patterns and Predictors of Sentinel Lymph Node Biopsy Utilization in High- and Low-Risk Thin Melanomas.
ASO Visual Abstract: Patterns and Predictors of Sentinel Lymph Node Biopsy Utilization in High- and Low-Risk Thin Melanomas.
Journal: Annals of surgical oncology
Published: February 24, 2026
Similar Doctors
Expertise in
12
conditions
Dr. Leora T. Yarboro
General Surgery
Expertise in
12
conditions
Dr. Leora T. Yarboro
General Surgery
Referral may be required

UVA Health University Medical Center

1215 Lee St, 
Charlottesville, VA 
 (0.1 miles away)
434-924-3627
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Leora Yarboro is a General Surgeon practicing medicine in Charlottesville, Virginia. Dr. Yarboro is highly rated in 12 conditions, according to our data. Her clinical expertise encompasses Aortic Dissection, Necrosis, Cystic Medial Necrosis of Aorta, Heart Bypass Surgery, and Coronary Artery Bypass Graft (CABG). Dr. Yarboro is currently accepting new patients.

Expertise in
23
conditions
Dr. Victor M. Zaydfudim
General Surgery
Expertise in
23
conditions
Dr. Victor M. Zaydfudim
General Surgery
Referral may be required

UVA Health Pancreatic Cancer Surgery Clinic

1240 Lee St, 
Charlottesville, VA 
 (0.1 miles away)
434-924-2839
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Victor Zaydfudim is a General Surgeon practicing medicine in Charlottesville, Virginia. Dr. Zaydfudim is highly rated in 23 conditions, according to our data. His clinical expertise encompasses Pancreatic Cancer, Familial Pancreatic Cancer, Cholangiocarcinoma (Bile Duct Cancer), Pancreatectomy, and Pancreaticoduodenectomy. Dr. Zaydfudim is currently accepting new patients.

Expertise in
18
conditions
Dr. Traci L. Hedrick
General Surgery
Expertise in
18
conditions
Dr. Traci L. Hedrick
General Surgery
Referral required
Before you request

UVA Health Digestive Health Center

1215 Lee St, 
Charlottesville, VA 
 (0.1 miles away)
434-243-3090
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Traci Hedrick is a General Surgeon practicing medicine in Charlottesville, Virginia. Dr. Hedrick is highly rated in 18 conditions, according to our data. Her clinical expertise encompasses Rectal Prolapse, Familial Colorectal Cancer, Hemorrhoids, Colostomy, and Ileostomy. Dr. Hedrick is currently accepting new patients.

Frequently Asked Questions about Dr. Craig L. Slingluff

How do I make an appointment with Dr. Craig L. Slingluff?

You can book an appointment with Dr. Craig L. Slingluff by calling their office at 434-924-9333. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Craig L. Slingluff a top-rated expert for Melanoma?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Craig L. Slingluff is classified as an Elite expert for Melanoma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Craig L. Slingluff specialize in?

While Dr. Craig L. Slingluff is a General Surgery, they have specific expertise in Melanoma, Merkel Cell Carcinoma, and Eccrine Porocarcinoma. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within General Surgery.

Does Dr. Craig L. Slingluff participate in research or clinical trials?

Yes. Dr. Craig L. Slingluff has published 167 articles and abstracts on conditions like Melanoma. You can view a list of Dr. Craig L. Slingluff's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Craig L. Slingluff accept my insurance?

Dr. Craig L. Slingluff accepts most major insurance plans, including HealthKeepers and Humana. We recommend calling the office directly at 434-924-9333 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Slingluff's expertise for a condition
ConditionClose
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile